Cox proportional hazard models for progression to AIDS in 96 study participants
. | . | Hazard ratio (95% CI) . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
. | No. cases* . | Univariate . | Multivariate 1, adjusted† . | Multivariate 2, adjusted‡ . | Multivariate 3, adjusted§ . | Multivariate 4, adjusted∥ . | ||||
| No. Gag IFNγ+ CD4+ T cells/mL | ||||||||||
| Tertiles¶ | ||||||||||
| 1 (Lowest)# | 27 | 1 | 1 | 1 | 1 | 1 | ||||
| 2 (Intermediate) | 28 | 0.60 (0.28-1.27) | 0.56 (0.26-1.19) | 0.56 (0.26-1.92) | 0.59 (0.28-1.27) | 0.48 (0.22-1.05) | ||||
| 3 (Highest) | 27 | 0.82 (0.38-1.76) | 0.65 (0.29-1.43) | 0.60 (0.27-1.35) | 0.55 (0.24-1.26) | 0.57 (0.26-1.27) | ||||
| No. Gag IL-2+ CD4+ T cells/mL | ||||||||||
| Tertiles** | ||||||||||
| 1 (Lowest)# | 27 | 1 | 1 | 1 | 1 | 1 | ||||
| 2 (Intermediate) | 27 | 1.23 (0.58-2.61) | 1.15 (0.54-2.48) | 1.21 (0.22-2.71) | 1.23 (0.56-2.73) | 1.29 (0.59-2.80) | ||||
| 3 (Highest) | 28 | 0.91 (0.41-2.02) | 0.99 (0.43-2.27) | 1.08 (0.46-2.52) | 1.09 (0.47-2.55) | 1.06 (0.46-2.47) | ||||
| No. Gag IL-2+ + IFNγ+ CD4+ T cells/mL | ||||||||||
| Tertiles†† | ||||||||||
| 1 (Lowest)# | 27 | 1 | 1 | 1 | 1 | 1 | ||||
| 2 (Intermediate) | 28 | 0.58 (0.28-1.19) | 0.57 (0.27-1.18) | 0.61 (0.28-1.32) | 0.62 (0.29-1.31) | 0.54 (0.25-1.14) | ||||
| 3 (Highest) | 27 | 0.50 (0.23-1.10) | 0.44 (0.20-0.98) | 0.47 (0.21-1.08) | 0.50 (0.22-1.13) | 0.40 (0.17-0.94) | ||||
. | . | Hazard ratio (95% CI) . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
. | No. cases* . | Univariate . | Multivariate 1, adjusted† . | Multivariate 2, adjusted‡ . | Multivariate 3, adjusted§ . | Multivariate 4, adjusted∥ . | ||||
| No. Gag IFNγ+ CD4+ T cells/mL | ||||||||||
| Tertiles¶ | ||||||||||
| 1 (Lowest)# | 27 | 1 | 1 | 1 | 1 | 1 | ||||
| 2 (Intermediate) | 28 | 0.60 (0.28-1.27) | 0.56 (0.26-1.19) | 0.56 (0.26-1.92) | 0.59 (0.28-1.27) | 0.48 (0.22-1.05) | ||||
| 3 (Highest) | 27 | 0.82 (0.38-1.76) | 0.65 (0.29-1.43) | 0.60 (0.27-1.35) | 0.55 (0.24-1.26) | 0.57 (0.26-1.27) | ||||
| No. Gag IL-2+ CD4+ T cells/mL | ||||||||||
| Tertiles** | ||||||||||
| 1 (Lowest)# | 27 | 1 | 1 | 1 | 1 | 1 | ||||
| 2 (Intermediate) | 27 | 1.23 (0.58-2.61) | 1.15 (0.54-2.48) | 1.21 (0.22-2.71) | 1.23 (0.56-2.73) | 1.29 (0.59-2.80) | ||||
| 3 (Highest) | 28 | 0.91 (0.41-2.02) | 0.99 (0.43-2.27) | 1.08 (0.46-2.52) | 1.09 (0.47-2.55) | 1.06 (0.46-2.47) | ||||
| No. Gag IL-2+ + IFNγ+ CD4+ T cells/mL | ||||||||||
| Tertiles†† | ||||||||||
| 1 (Lowest)# | 27 | 1 | 1 | 1 | 1 | 1 | ||||
| 2 (Intermediate) | 28 | 0.58 (0.28-1.19) | 0.57 (0.27-1.18) | 0.61 (0.28-1.32) | 0.62 (0.29-1.31) | 0.54 (0.25-1.14) | ||||
| 3 (Highest) | 27 | 0.50 (0.23-1.10) | 0.44 (0.20-0.98) | 0.47 (0.21-1.08) | 0.50 (0.22-1.13) | 0.40 (0.17-0.94) | ||||
CI indicates 95% confidence level.
Because of missing data on the covariates of the multivariate model, it is possible that a subject was excluded from the analyses
Adjusted for baseline log HIV RNA (continuous) and square root CD4+ T-cell count (continuous)
Adjusted for baseline log HIV RNA (continuous), square root CD4+ T-cell numbers (continuous), and percentage of Ki67+CD4+ T cells (2 categories: 1.6%-5.3%; 5.3%-15.5%)
Adjusted for baseline log HIV RNA (continuous), square root CD4+ T-cell numbers (continuous), and percentage of CD38+CD4+ T cells (2 categories: 40.0%-66.1%; 66.1%-91.1%)
Adjusted for baseline log HIV RNA (continuous), square root CD4+ T-cell numbers (continuous), and percentage of CD38+HLA-DR+CD8+ T cells (2 categories: 0.5%-3.6%; 3.6%-71.4%)
Ranges: first tertile, 1-141 cells/mL; second tertile, 141-365 cells/mL, third tertile, 365-5184 cells/mL
Reference category
Ranges: first tertile, 1-54 cells/mL; second tertile, 54-128 cells/mL; third tertile, 128-6794 cells/mL
Ranges: first tertile, 1-151 cells/mL; second tertile, 151-360 cells/mL; third tertile, 360-1316 cells/mL